2021 Q4 Form 10-K Financial Statement

#000155837022004823 Filed on March 31, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $8.550M $38.35M $19.50M
YoY Change -56.15% -39.03% 9.8%
Cost Of Revenue $3.150M $16.35M $2.750M
YoY Change 14.55% 50.36% -6.78%
Gross Profit $5.400M $22.00M $16.74M
YoY Change -67.74% -57.71% 13.03%
Gross Profit Margin 63.16% 57.37% 85.85%
Selling, General & Admin $3.470M $12.73M $2.950M
YoY Change 17.63% 14.18% -1.99%
% of Gross Profit 64.26% 57.86% 17.62%
Research & Development $7.640M $29.73M $10.95M
YoY Change -30.23% -22.1% 13.83%
% of Gross Profit 141.48% 135.15% 65.41%
Depreciation & Amortization $260.0K $1.100M $290.0K
YoY Change -10.34% -15.38% -29.27%
% of Gross Profit 4.81% 5.0% 1.73%
Operating Expenses $11.11M $42.46M $13.91M
YoY Change -20.13% -13.89% 10.31%
Operating Profit -$5.710M -$20.46M $2.830M
YoY Change -301.77% -855.06% 28.64%
Interest Expense -$910.0K -$5.030M -$2.440M
YoY Change -62.7% -31.84% 27.75%
% of Operating Profit -86.22%
Other Income/Expense, Net -$50.00K -$7.120M
YoY Change -22.89%
Pretax Income -$6.670M -$27.58M $400.0K
YoY Change -1767.5% 322.84% 37.93%
Income Tax
% Of Pretax Income
Net Earnings -$6.670M -$27.58M $400.0K
YoY Change -1767.5% 322.84% 37.93%
Net Earnings / Revenue -78.01% -71.92% 2.05%
Basic Earnings Per Share -$0.62
Diluted Earnings Per Share -$0.15 -$0.62 $0.01
COMMON SHARES
Basic Shares Outstanding 45.56M 44.14M 33.34M
Diluted Shares Outstanding 44.14M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.00M $39.00M $18.30M
YoY Change 113.11% 113.11% 2.81%
Cash & Equivalents $38.99M $39.00M $18.27M
Short-Term Investments
Other Short-Term Assets $1.285M $1.300M $2.096M
YoY Change -38.69% -94.17% 14.41%
Inventory $17.95M $18.00M $13.08M
Prepaid Expenses $905.0K $841.0K
Receivables $3.442M $3.400M $2.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $61.67M $61.70M $55.72M
YoY Change 10.67% 10.77% 71.57%
LONG-TERM ASSETS
Property, Plant & Equipment $4.962M $9.900M $4.845M
YoY Change 2.41% -4.81% -8.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.100M $2.100M $1.800M
YoY Change 16.67% 16.67% -10.0%
Total Long-Term Assets $12.00M $12.00M $12.21M
YoY Change -1.74% -1.64% -5.44%
TOTAL ASSETS
Total Short-Term Assets $61.67M $61.70M $55.72M
Total Long-Term Assets $12.00M $12.00M $12.21M
Total Assets $73.67M $73.70M $67.93M
YoY Change 8.44% 8.54% 49.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.43M $7.000M $13.93M
YoY Change 18.0% -2.78% 16.98%
Accrued Expenses $11.98M $15.50M $9.586M
YoY Change 24.98% 19.23% 30.24%
Deferred Revenue $8.550M $5.394M
YoY Change 58.51% -66.98%
Short-Term Debt $0.00 $0.00 $4.100M
YoY Change -100.0% -100.0% -4.65%
Long-Term Debt Due $54.40M
YoY Change
Total Short-Term Liabilities $33.18M $33.20M $86.47M
YoY Change -61.63% -61.62% 115.24%
LONG-TERM LIABILITIES
Long-Term Debt $27.90M $27.90M $100.0K
YoY Change 27800.0% 27800.0% -99.81%
Other Long-Term Liabilities $18.60M $18.60M $51.00K
YoY Change 36370.59% 121.43% -89.98%
Total Long-Term Liabilities $46.53M $46.50M $8.497M
YoY Change 447.55% 447.06% -88.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.18M $33.20M $86.47M
Total Long-Term Liabilities $46.53M $46.50M $8.497M
Total Liabilities $79.70M $79.70M $94.97M
YoY Change -16.08% -16.11% -17.93%
SHAREHOLDERS EQUITY
Retained Earnings -$374.9M -$347.4M
YoY Change 7.94% 1.91%
Common Stock $368.9M $320.3M
YoY Change 15.17% 18.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.036M -$6.000M -$27.04M
YoY Change
Total Liabilities & Shareholders Equity $73.67M $73.70M $67.93M
YoY Change 8.44% 8.54% 49.66%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$6.670M -$27.58M $400.0K
YoY Change -1767.5% 322.84% 37.93%
Depreciation, Depletion And Amortization $260.0K $1.100M $290.0K
YoY Change -10.34% -15.38% -29.27%
Cash From Operating Activities -$5.090M -$10.29M -$7.550M
YoY Change -32.58% -60.6% 104.61%
INVESTING ACTIVITIES
Capital Expenditures $450.0K $1.459M $280.0K
YoY Change 60.71% 122.75% 833.33%
Acquisitions
YoY Change
Other Investing Activities $37.88M $109.0K $7.860M
YoY Change 381.93% -134.17% 15620.0%
Cash From Investing Activities $37.44M $18.92M $7.590M
YoY Change 393.28% -194.83% 25200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.575M
YoY Change 76.19%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.040M 12.08M 4.650M
YoY Change -186.88% -74.01%
NET CHANGE
Cash From Operating Activities -5.090M -10.29M -7.550M
Cash From Investing Activities 37.44M 18.92M 7.590M
Cash From Financing Activities -4.040M 12.08M 4.650M
Net Change In Cash 28.31M 20.72M 4.690M
YoY Change 503.62% 4280.55% -228.14%
FREE CASH FLOW
Cash From Operating Activities -$5.090M -$10.29M -$7.550M
Capital Expenditures $450.0K $1.459M $280.0K
Free Cash Flow -$5.540M -$11.74M -$7.830M
YoY Change -29.25% -56.12% 110.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14838213
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29148047
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44140233
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001006281
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45556647
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34765280
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-33357
CY2021 dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
CY2021 dei City Area Code
CityAreaCode
201
CY2021 dei Local Phone Number
LocalPhoneNumber
696-9345
CY2021 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
PLX
CY2021 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1799000
CY2021Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
2077000
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4845000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4962000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5567000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4960000
CY2020Q4 us-gaap Assets
Assets
67934000
CY2021Q4 us-gaap Assets
Assets
73665000
CY2020Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
7221000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
6986000
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
13926000
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
16433000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1420000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1207000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5394000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8550000
CY2020Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
54427000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4086000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
86474000
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
85100000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46316129
CY2021 dei Auditor Name
AuditorName
Kesselman & Kesselman C.P.A.s
CY2021 dei Auditor Firm
AuditorFirmId
1309
CY2021 dei Auditor Location
AuditorLocation
Tel Aviv, Israel
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18265000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38985000
CY2020Q4 plx Short Term Bank Deposits
ShortTermBankDeposits
20280000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2000000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3442000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2096000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1285000
CY2020Q4 us-gaap Inventory Net
InventoryNet
13082000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
55723000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
61666000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33176000
CY2021Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
27887000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1716000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11790000
CY2020Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2263000
CY2021Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2472000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4467000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4376000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
8497000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
46525000
CY2020Q4 us-gaap Liabilities
Liabilities
94971000
CY2021Q4 us-gaap Liabilities
Liabilities
79701000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34765280
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45556647
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
46000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
320280000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
368852000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347352000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-374934000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67934000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73665000
CY2019 us-gaap Revenues
Revenues
54693000
CY2020 us-gaap Revenues
Revenues
62898000
CY2021 us-gaap Revenues
Revenues
38350000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
10895000
CY2020 us-gaap Cost Of Revenue
CostOfRevenue
10873000
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
16349000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44616000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38167000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29734000
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9899000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11148000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12729000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-10717000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
2710000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-20462000
CY2019 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7966000
CY2020 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
9671000
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
7521000
CY2019 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
407000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
438000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
401000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7559000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9233000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7120000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-18276000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6523000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27582000
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14838213
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29148047
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
51000
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-831000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2991000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44140233
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-52881000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
835000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-18276000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70322000
CY2020 plx Issuance Of Common Stock And Warrants Net Of Issuance Cost Value
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
41343000
CY2020 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
4867000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2264000
CY2020 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
862000
CY2020 plx Stock Issued During Period Value Warrants Exercises
StockIssuedDuringPeriodValueWarrantsExercises
472000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6523000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-27037000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37625000
CY2021 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
8575000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1405000
CY2021 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
970000
CY2021 plx Reacquisition Of Equity Component Of Convertible Notes
ReacquisitionOfEquityComponentOfConvertibleNotes
12019000
CY2021 plx Equity Component Of Convertible Notes Net Of Transaction Costs
EquityComponentOfConvertibleNotesNetOfTransactionCosts
12027000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27582000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-18276000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-6523000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-27582000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
835000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3126000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2375000
CY2019 us-gaap Depreciation
Depreciation
1617000
CY2020 us-gaap Depreciation
Depreciation
1302000
CY2021 us-gaap Depreciation
Depreciation
1118000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-378000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-171000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-417000
CY2019 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-10000
CY2020 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-494000
CY2021 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
133000
CY2019 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
58000
CY2020 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
28000
CY2021 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
100000
CY2020 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3470000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2673000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9580000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-26205000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
13230000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-188000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2091000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1032000
CY2019 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
110000
CY2020 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-95000
CY2021 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-241000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-414000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4927000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4872000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2735000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2274000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2385000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-482000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-458000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-51000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19358000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26106000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10285000
CY2020 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
20000000
CY2021 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
37835000
CY2021 plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
57835000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
627000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
655000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1459000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
53000
CY2019 us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
259000
CY2020 us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
-384000
CY2021 us-gaap Increase Decrease Of Restricted Investments
IncreaseDecreaseOfRestrictedInvestments
-436000
CY2019 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3000
CY2020 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-319000
CY2021 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
109000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-883000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19952000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18921000
CY2021 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
30036000
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
215000
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4086000
CY2020 plx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
41343000
CY2021 plx Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
37625000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4867000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8575000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
472000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46467000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12078000
CY2019 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
225000
CY2020 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
64000
CY2021 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
6000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20016000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
473000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20720000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37808000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17792000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18265000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17792000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18265000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38985000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
98000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
317000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
94000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
388000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
632000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
309000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
4344000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
4344000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
3410000
CY2019 plx Interest Received Net
InterestReceivedNet
407000
CY2020 plx Interest Received Net
InterestReceivedNet
438000
CY2021 plx Interest Received Net
InterestReceivedNet
379000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40200000
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4.60
CY2020Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
41300000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">c.    Use of estimates in the preparation of financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates relate to revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><span style="background:#ffffff;">The severity, magnitude and duration, as well as the economic consequences, of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. As a result, the accounting estimates and assumptions may change over time in response to COVID-19.</span></p>
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28502017
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7838120
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22850682
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37714000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31923000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32752000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4845000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4962000
CY2019 us-gaap Depreciation
Depreciation
1600000
CY2020 us-gaap Depreciation
Depreciation
1300000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 36pt;">m.    Concentration of credit risks and trade receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company’s deposits are instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">believe it is exposed to any significant credit risk on these instruments. The Company’s trade receivables represent amounts to be received from its customers. The Company does not require its customers to post collateral with respect to receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">As of December 31, 2021, the accounts receivables balance was composed of $2.2 million from Fiocruz and $1.2 million from Chiesi.</p>
CY2021 us-gaap Depreciation
Depreciation
1100000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36768000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3347000
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3166000
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2887000
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3262000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6848000
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11526000
CY2020Q4 us-gaap Inventory Net
InventoryNet
13082000
CY2021Q4 us-gaap Inventory Net
InventoryNet
17954000
CY2019 us-gaap Inventory Write Down
InventoryWriteDown
500000
CY2020 us-gaap Inventory Write Down
InventoryWriteDown
300000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
400000
CY2019 plx Employee Severance Obligation Payment
EmployeeSeveranceObligationPayment
143000
CY2020 plx Employee Severance Obligation Payment
EmployeeSeveranceObligationPayment
121000
CY2021 plx Employee Severance Obligation Payment
EmployeeSeveranceObligationPayment
108000
CY2019 us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
784000
CY2020 us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
885000
CY2021 us-gaap Postemployment Benefits Period Expense
PostemploymentBenefitsPeriodExpense
990000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
642000
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
747000
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
857000
CY2019 us-gaap Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax
DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
58000
CY2020 us-gaap Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax
DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
28000
CY2021 us-gaap Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax
DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
100000
CY2021Q4 plx Number Of Employees To Receive Benefits During Next Five Years
NumberOfEmployeesToReceiveBenefitsDuringNextFiveYears
4
CY2021Q4 plx Benefits Payable During Next Five Years
BenefitsPayableDuringNextFiveYears
72000
CY2021 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2021 plx Lessee Operating Lease Number Of Renewal Term Extensions
LesseeOperatingLeaseNumberOfRenewalTermExtensions
1
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
496000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1219000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1382000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1632000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1329000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1289000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1391000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.127
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.127
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1207000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1025000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
872000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
853000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
848000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
4528000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9333000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3750000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5583000
CY2021Q4 plx Common Stock Number Of Voting Rights
CommonStockNumberOfVotingRights
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1786256
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y10M24D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
835000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3126000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2375000
CY2021Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8749999
CY2021Q1 us-gaap Share Price
SharePrice
4.60
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
40200000
CY2016Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
2384673
CY2017Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
9500000
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
247900000
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
231400000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
9598000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7217000
CY2020Q4 plx Deferred Tax Assets Other Timing Differences
DeferredTaxAssetsOtherTimingDifferences
40000
CY2021Q4 plx Deferred Tax Assets Other Timing Differences
DeferredTaxAssetsOtherTimingDifferences
-1989000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
54122000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56292000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
63760000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
61520000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2020Q4 plx Other Assets Institutions Current
OtherAssetsInstitutionsCurrent
771000
CY2021Q4 plx Other Assets Institutions Current
OtherAssetsInstitutionsCurrent
311000
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
436000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
841000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
905000
CY2020Q4 plx Other Assets Sundry Current
OtherAssetsSundryCurrent
48000
CY2021Q4 plx Other Assets Sundry Current
OtherAssetsSundryCurrent
69000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2096000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1285000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1460000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1562000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
555000
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
767000
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1526000
CY2021Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
1506000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9586000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11981000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
482000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
522000
CY2020Q4 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
317000
CY2021Q4 plx Accounts Payable Property And Equipment Suppliers Current
AccountsPayablePropertyAndEquipmentSuppliersCurrent
95000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13926000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16433000

Files In Submission

Name View Source Status
0001558370-22-004823-index-headers.html Edgar Link pending
0001558370-22-004823-index.html Edgar Link pending
0001558370-22-004823.txt Edgar Link pending
0001558370-22-004823-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20211231.xsd Edgar Link pending
plx-20211231x10k.htm Edgar Link pending
plx-20211231x10k001.jpg Edgar Link pending
plx-20211231x10k002.jpg Edgar Link pending
plx-20211231x10k003.jpg Edgar Link pending
plx-20211231x10k005.jpg Edgar Link pending
plx-20211231x10k_htm.xml Edgar Link completed
plx-20211231xex23d1.htm Edgar Link pending
plx-20211231xex23d1001.jpg Edgar Link pending
plx-20211231xex31d1.htm Edgar Link pending
plx-20211231xex31d2.htm Edgar Link pending
plx-20211231xex32d1.htm Edgar Link pending
plx-20211231xex32d2.htm Edgar Link pending
plx-20211231_cal.xml Edgar Link unprocessable
plx-20211231_def.xml Edgar Link unprocessable
plx-20211231_lab.xml Edgar Link unprocessable
plx-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending